KR101989390B1 - 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물 - Google Patents

뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물 Download PDF

Info

Publication number
KR101989390B1
KR101989390B1 KR1020047001544A KR20047001544A KR101989390B1 KR 101989390 B1 KR101989390 B1 KR 101989390B1 KR 1020047001544 A KR1020047001544 A KR 1020047001544A KR 20047001544 A KR20047001544 A KR 20047001544A KR 101989390 B1 KR101989390 B1 KR 101989390B1
Authority
KR
South Korea
Prior art keywords
acid
arachidonic acid
fatty acid
triglyceride
arachidonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047001544A
Other languages
English (en)
Korean (ko)
Other versions
KR20040026697A (ko
Inventor
아키모토겐고
가와시마히로시
오노요시코
오카이치히로시게
오카이치요우코
Original Assignee
산토리 홀딩스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19066953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101989390(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 산토리 홀딩스 가부시키가이샤 filed Critical 산토리 홀딩스 가부시키가이샤
Publication of KR20040026697A publication Critical patent/KR20040026697A/ko
Application granted granted Critical
Publication of KR101989390B1 publication Critical patent/KR101989390B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Non-Alcoholic Beverages (AREA)
KR1020047001544A 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물 Expired - Lifetime KR101989390B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2001-00235519 2001-08-02
JP2001235519A JP2003048831A (ja) 2001-08-02 2001-08-02 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
PCT/JP2002/000671 WO2003013497A1 (en) 2001-08-02 2002-01-29 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026429A Division KR20170109693A (ko) 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선 작용을 가지는 조성물

Publications (2)

Publication Number Publication Date
KR20040026697A KR20040026697A (ko) 2004-03-31
KR101989390B1 true KR101989390B1 (ko) 2019-06-14

Family

ID=19066953

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047001544A Expired - Lifetime KR101989390B1 (ko) 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물
KR1020177026429A Ceased KR20170109693A (ko) 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선 작용을 가지는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177026429A Ceased KR20170109693A (ko) 2001-08-02 2002-01-29 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선 작용을 가지는 조성물

Country Status (13)

Country Link
US (1) US10744146B2 (enExample)
EP (1) EP1419768B1 (enExample)
JP (1) JP2003048831A (enExample)
KR (2) KR101989390B1 (enExample)
CN (2) CN1561206A (enExample)
AT (1) ATE520395T1 (enExample)
AU (1) AU2008201045B2 (enExample)
CA (1) CA2456049C (enExample)
CY (1) CY1111808T1 (enExample)
DK (1) DK1419768T3 (enExample)
ES (1) ES2369074T3 (enExample)
PT (1) PT1419768E (enExample)
WO (1) WO2003013497A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DK1542670T3 (da) * 2002-09-24 2013-05-27 Suntory Holdings Ltd Sammensætning omfattende arachidonsyre alene eller i kombination med docosahexanoensyre til forøgelse af kognitive evner hos voksne
EP1605930B1 (en) 2003-03-27 2020-06-03 Suntory Holdings Limited Use of arachidonic acid for normalization of infradian rhythm
EP1605768A2 (en) 2003-03-27 2005-12-21 Suntory Limited Lipid-improving agent and composition containing lipid-improvimg agent
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
GB0319358D0 (en) * 2003-08-18 2003-09-17 Btg Int Ltd Treatment of neurodegenerative conditions
JP2007502805A (ja) * 2003-08-18 2007-02-15 ビーティージー・インターナショナル・リミテッド 神経変性状態の処置
GB2442164B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442161B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Triglycerides
JP4522075B2 (ja) 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
AU2005208832A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
WO2005083101A1 (ja) * 2004-03-01 2005-09-09 Suntory Limited 長鎖高度不飽和脂肪酸を構成要素として含むリン脂質の製造方法、およびその利用
ES2342305T3 (es) 2004-08-12 2010-07-05 Nippon Suisan Kaisha, Ltd. Metodo de produccion de acidos grasos poliinsaturados usando una nueva tecnica de conservacion de celulas.
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4849806B2 (ja) 2005-02-08 2012-01-11 日本水産株式会社 新規な菌体処理方法を用いた高度不飽和脂肪酸の製造方法
US8241868B2 (en) 2005-02-08 2012-08-14 Nippon Suisan Kaisha, Ltd. Production of polyunsaturated fatty acids using cell treatment method
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
AU2006251569B2 (en) * 2005-05-23 2012-06-21 Massachusetts Institute Of Technology Compostions containing pufa and/or uridine and methods of use thereof
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
AU2006299665B2 (en) * 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
DE102005058369A1 (de) * 2005-12-06 2007-06-14 Lts Lohmann Therapie-Systeme Ag Ungesättigte Fettsäuren als Thrombin-Inhibitoren
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
PT2001293T (pt) * 2006-04-03 2018-11-28 Accera Inc Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
CN101631542B (zh) * 2006-12-28 2011-12-21 三得利控股株式会社 神经再生剂
PT2144618E (pt) 2007-03-28 2013-07-08 Aker Biomarine Asa Composições bioeficazes de óleo de krill
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
MX374545B (es) * 2007-06-29 2025-03-06 Dsm Ip Assets Bv Produccion y purificacion de esteres de acidos grasos poliinsaturados.
JP2009019025A (ja) * 2007-07-13 2009-01-29 Suntory Ltd 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤
WO2009018478A2 (en) 2007-07-31 2009-02-05 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
JP2009219500A (ja) * 2009-06-22 2009-10-01 Suntory Holdings Ltd 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2011136948A (ja) * 2009-12-28 2011-07-14 Nisshin Oillio Group Ltd うつ病又はうつ状態の予防又は治療用油脂組成物
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
JP6095615B2 (ja) * 2014-07-22 2017-03-15 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
KR102310765B1 (ko) 2015-02-11 2021-10-12 에이커 바이오마린 앤탁틱 에이에스 지질 조성물
JP2016172770A (ja) * 2016-06-29 2016-09-29 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
US10456368B2 (en) 2016-09-26 2019-10-29 Garrett E. Wdowin Compositions for mitigating brain trauma and methods thereof
CN110747239B (zh) * 2019-11-26 2021-06-22 瞿瀚鹏 富含Sn-2位ARA的微生物油脂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021037A1 (en) * 1995-01-03 1996-07-11 Martek Biosciences Corporation Arachidonic acid and methods for the production and use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB111282A (en) 1916-11-10 Ets De Dion Bouton Improvements in or relating to Roller Bearings.
US4668704A (en) * 1982-08-09 1987-05-26 Regents Of The University Of California Method for protecting and healing gastro-duodenal mucosa and the liver of mammals
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPS63297342A (ja) 1987-05-28 1988-12-05 Nisshin Oil Mills Ltd:The 合成油脂ならびにこれを含有する脂肪乳剤輸液および経腸栄養剤
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JP3467794B2 (ja) 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
CA2596241C (en) 1993-06-09 2011-04-19 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
DE59502779D1 (de) 1994-10-05 1998-08-13 Milupa Gmbh & Co Kg Phospholipidhaltige fettmischung mit lcp-fettsäuren
JPH08143454A (ja) 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
JPH08214891A (ja) 1995-02-17 1996-08-27 Osaka City 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法
EP0831805A1 (en) 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
JPH0923817A (ja) 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
JPH0930962A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
CN1058845C (zh) 1996-01-31 2000-11-29 高世虎 强化营养豆奶粉
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP4034370B2 (ja) * 1996-09-27 2008-01-16 雪印乳業株式会社 脳機能改善剤及び栄養組成物
JP4633204B2 (ja) 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
JPH10155459A (ja) 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
FR2762993B1 (fr) 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
KR100255868B1 (ko) * 1997-06-28 2000-05-01 김영환 2의 보수 복소수 곱셈기
ATE230935T1 (de) 1997-07-22 2003-02-15 Nestle Sa Lipidzusammensetzung für säuglingsnährpräparat und herstellungsverfahren
JP2970804B2 (ja) 1997-07-23 1999-11-02 株式会社フジクラ 難燃性シート
US6225444B1 (en) * 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
NZ511071A (en) 1998-10-15 2004-01-30 Dsm N PUFA supplements
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
JP2001031586A (ja) 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US20020019444A1 (en) 2000-05-08 2002-02-14 Edward Hogestatt Anandamide and structurally related lipids as vanilloid receptor modulators
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US20020077355A1 (en) 2000-05-30 2002-06-20 Liao James K. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
JP2003535892A (ja) 2000-06-23 2003-12-02 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム ２−アラキドニルグリセロール（２−ＡＧ）−腫瘍壊死因子−αの阻害剤および閉鎖性頭部損傷における脳の神経保護因子
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
CA2424570A1 (en) 2000-09-07 2002-03-14 University Of Maryland Biotechnology Institute Use of arachidonic acid for enhanced culturing of fish larvae and broodstock
ATE430794T1 (de) 2001-03-09 2009-05-15 Nestle Sa Öl, das langkettige, mehrfach ungesättigte fettsäuren aus biomassen enthält, verfahren zur herstellung, lebensmittel, nahrungsmittelzusammensetzung, kosmetische oder pharmazeutische zusammensetzung, die dieses enthält
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
EP1997498B1 (en) 2001-06-18 2012-04-25 Neptune Technologies & Bioressources Inc. Krill extracts for prevention and/or treatment of cardiovascular diseases
ATE457357T1 (de) 2001-07-02 2010-02-15 Suntory Holdings Ltd Verfahren zur herstellung von fett mit triglyceridhaltiger hochungesättigter fettsäure
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2003113120A (ja) 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
BR0309740A (pt) 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
JP4522257B2 (ja) 2002-09-13 2010-08-11 サントリーホールディングス株式会社 エステル交換油脂またはトリグリセリドの製造方法
GB0221480D0 (en) 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
DK1542670T3 (da) * 2002-09-24 2013-05-27 Suntory Holdings Ltd Sammensætning omfattende arachidonsyre alene eller i kombination med docosahexanoensyre til forøgelse af kognitive evner hos voksne
EP1605930B1 (en) 2003-03-27 2020-06-03 Suntory Holdings Limited Use of arachidonic acid for normalization of infradian rhythm
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
JP2007502805A (ja) 2003-08-18 2007-02-15 ビーティージー・インターナショナル・リミテッド 神経変性状態の処置
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU2005208832A1 (en) 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
JP4868199B2 (ja) 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP2006083136A (ja) 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5697293B2 (ja) 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021037A1 (en) * 1995-01-03 1996-07-11 Martek Biosciences Corporation Arachidonic acid and methods for the production and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문 J. Neurochemistry, Vol. 62 (1994)

Also Published As

Publication number Publication date
ATE520395T1 (de) 2011-09-15
DK1419768T3 (da) 2011-09-12
AU2008201045A1 (en) 2008-04-03
EP1419768B1 (en) 2011-08-17
CY1111808T1 (el) 2015-10-07
AU2008201045B2 (en) 2011-02-17
WO2003013497A1 (en) 2003-02-20
CA2456049C (en) 2012-10-16
ES2369074T3 (es) 2011-11-25
KR20170109693A (ko) 2017-09-29
KR20040026697A (ko) 2004-03-31
PT1419768E (pt) 2011-10-13
CA2456049A1 (en) 2003-02-20
EP1419768A4 (en) 2005-07-06
US20040266874A1 (en) 2004-12-30
EP1419768A1 (en) 2004-05-19
JP2003048831A (ja) 2003-02-21
US10744146B2 (en) 2020-08-18
CN1561206A (zh) 2005-01-05
CN101336913A (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
KR101989390B1 (ko) 뇌기능 저하에 기인하는 증상이나 질환의 예방 또는 개선작용을 가지는 조성물
CN100418519C (zh) 用于增强认知能力的含有花生四烯酸或其与二十二碳六烯酸的组合的组合物
US8367729B2 (en) Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
AU2005283696B2 (en) Composition with preventive or improvement effect on stress-induced brain function impairment and related symptoms or diseases
EP1605930B1 (en) Use of arachidonic acid for normalization of infradian rhythm
JP5967855B2 (ja) 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
TWI445528B (zh) The use of arachidonic acid as a constituent fatty acid triglyceride for the manufacture of a pharmaceutical composition and a food product for preventing or ameliorating a symptom or a disease caused by aging of the blood vessel caused by a decrease in blood vessel elasticity, The manufacturing method
JP5496163B2 (ja) 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物

Legal Events

Date Code Title Description
AMND Amendment
PA0105 International application

Patent event date: 20040131

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070129

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071206

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20090430

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20160816

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170621

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160816

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20071206

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170919

PJ0201 Trial against decision of rejection

Patent event date: 20170919

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20170621

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2017101004456

Request date: 20170919

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20170919

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20170919

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170203

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20160405

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070129

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20040131

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2017101004456; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170919

Effective date: 20190314

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20190314

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20170919

Decision date: 20190314

Appeal identifier: 2017101004456

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20190319

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20190314

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190610

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190611

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PC1801 Expiration of term

Termination date: 20220729

Termination category: Expiration of duration